SG11202006712XA - Treatment of ophthalmologic diseases - Google Patents
Treatment of ophthalmologic diseasesInfo
- Publication number
- SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA SG 11202006712X A SG11202006712X A SG 11202006712XA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- ophthalmologic diseases
- ophthalmologic
- diseases
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862627103P | 2018-02-06 | 2018-02-06 | |
US201862729333P | 2018-09-10 | 2018-09-10 | |
PCT/EP2019/052704 WO2019154776A1 (fr) | 2018-02-06 | 2019-02-05 | Traitement de maladies ophthalmologiques |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006712XA true SG11202006712XA (en) | 2020-08-28 |
Family
ID=65352014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006712XA SG11202006712XA (en) | 2018-02-06 | 2019-02-05 | Treatment of ophthalmologic diseases |
Country Status (12)
Country | Link |
---|---|
US (2) | US20210139576A1 (fr) |
EP (1) | EP3749359A1 (fr) |
JP (3) | JP7005772B2 (fr) |
KR (1) | KR20200119274A (fr) |
CN (1) | CN111699004A (fr) |
AU (1) | AU2019219004A1 (fr) |
CA (1) | CA3088355A1 (fr) |
IL (1) | IL276383B2 (fr) |
MX (1) | MX2020007527A (fr) |
SG (1) | SG11202006712XA (fr) |
TW (1) | TWI831764B (fr) |
WO (1) | WO2019154776A1 (fr) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
CA3010056A1 (fr) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Anticorps et conjugues de ceux-ci |
EP3743091A4 (fr) | 2018-01-26 | 2021-12-15 | The Regents of the University of California | Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf |
JP7403553B2 (ja) * | 2019-08-06 | 2023-12-22 | エフ. ホフマン-ラ ロシュ アーゲー | 眼科の疾患の個別化された治療 |
EP4041312A4 (fr) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Procédés de traitement d'un trouble oculaire |
WO2021108255A1 (fr) | 2019-11-25 | 2021-06-03 | The Regents Of The University Of California | Inhibiteurs de vegf à action prolongée pour néovascularisation intraoculaire |
KR20230061458A (ko) | 2020-09-04 | 2023-05-08 | 에프. 호프만-라 로슈 아게 | Vegf-a 및 ang2에 결합하는 항체 및 사용 방법 |
WO2022057888A1 (fr) * | 2020-09-17 | 2022-03-24 | 江苏恒瑞医药股份有限公司 | Molécule de liaison à l'antigène bispécifique se liant spécifiquement au vegf et à l'ang-2 |
EP4313148A1 (fr) * | 2021-03-30 | 2024-02-07 | Abpro Corporation | Méthodes de traitement de la néovascularisation choroïdienne à l'aide d'anticorps multi-spécifiques anti-ang2 x vegf |
CN117100845A (zh) * | 2022-10-24 | 2023-11-24 | 景泽生物医药(合肥)股份有限公司 | 重组人奥克纤溶酶在制备治疗脉络膜血管疾病药物中的用途 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
IL132560A0 (en) | 1997-05-02 | 2001-03-19 | Genentech Inc | A method for making multispecific antibodies having heteromultimeric and common components |
AU2006232287B2 (en) | 2005-03-31 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
PL1999154T3 (pl) | 2006-03-24 | 2013-03-29 | Merck Patent Gmbh | Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe |
EP2035456A1 (fr) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production d'anticorps bispécifiques |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
PL2235064T3 (pl) | 2008-01-07 | 2016-06-30 | Amgen Inc | Sposób otrzymywania cząsteczek przeciwciał z heterodimerycznymi fc z zastosowaniem kierujących efektów elektrostatycznych |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
EP2424567B1 (fr) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Procédé de fabrication de molécules hétéromultimères |
EP3112382A1 (fr) | 2009-12-29 | 2017-01-04 | Emergent Product Development Seattle, LLC | Protéines à liaison hétérodimère et leurs utilisations |
AR080794A1 (es) | 2010-03-26 | 2012-05-09 | Hoffmann La Roche | Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2 |
CA2797981C (fr) | 2010-05-14 | 2019-04-23 | Rinat Neuroscience Corporation | Proteines heterodimeriques et leurs procedes de production et de purification |
CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
KR20180023015A (ko) * | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
PT2838917T (pt) | 2012-04-20 | 2019-09-12 | Merus Nv | Métodos e meios para a produção de moléculas similares a ig heterodiméricas |
AU2013288641B2 (en) * | 2012-07-13 | 2017-07-06 | Roche Glycart Ag | Bispecific anti-VEGF/anti-ANG-2 antibodies and their use in the treatment of ocular vascular diseases |
HUE058912T2 (hu) * | 2012-08-21 | 2022-09-28 | Opko Pharmaceuticals Llc | Liposzóma készítmények |
WO2014177459A2 (fr) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Anticorps asymétriques modifiés liant à la récepteur fc et procédés d'utilisation |
KR20150063728A (ko) | 2013-12-02 | 2015-06-10 | 삼성전자주식회사 | 항 VEGF-C/항 Ang2 이중 특이 항체 |
TWI761959B (zh) * | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
CN106999511A (zh) * | 2014-12-11 | 2017-08-01 | 拜耳医药保健有限责任公司 | 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗 |
AR103477A1 (es) * | 2015-01-28 | 2017-05-10 | Lilly Co Eli | Compuestos de vegfa / ang2 |
CN109310756B (zh) * | 2016-05-13 | 2022-06-28 | 奥美药业有限公司 | 新型血管生成素2,vegf双特异性拮抗剂 |
-
2019
- 2019-02-05 CN CN201980011416.4A patent/CN111699004A/zh active Pending
- 2019-02-05 EP EP19703978.7A patent/EP3749359A1/fr active Pending
- 2019-02-05 CA CA3088355A patent/CA3088355A1/fr active Pending
- 2019-02-05 SG SG11202006712XA patent/SG11202006712XA/en unknown
- 2019-02-05 KR KR1020207025450A patent/KR20200119274A/ko not_active IP Right Cessation
- 2019-02-05 AU AU2019219004A patent/AU2019219004A1/en active Pending
- 2019-02-05 WO PCT/EP2019/052704 patent/WO2019154776A1/fr unknown
- 2019-02-05 JP JP2020536578A patent/JP7005772B2/ja active Active
- 2019-02-05 IL IL276383A patent/IL276383B2/en unknown
- 2019-02-05 MX MX2020007527A patent/MX2020007527A/es unknown
- 2019-02-11 TW TW108104518A patent/TWI831764B/zh active
-
2020
- 2020-08-05 US US16/985,477 patent/US20210139576A1/en not_active Abandoned
-
2022
- 2022-01-05 JP JP2022000341A patent/JP7273204B2/ja active Active
-
2023
- 2023-02-09 US US18/166,996 patent/US20230416353A1/en active Pending
- 2023-04-27 JP JP2023073187A patent/JP2023099094A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019154776A1 (fr) | 2019-08-15 |
JP7005772B2 (ja) | 2022-02-10 |
JP2021506947A (ja) | 2021-02-22 |
EP3749359A1 (fr) | 2020-12-16 |
MX2020007527A (es) | 2020-09-09 |
TWI831764B (zh) | 2024-02-11 |
JP7273204B2 (ja) | 2023-05-12 |
CN111699004A (zh) | 2020-09-22 |
AU2019219004A1 (en) | 2020-07-16 |
JP2022046738A (ja) | 2022-03-23 |
US20210139576A1 (en) | 2021-05-13 |
US20230416353A1 (en) | 2023-12-28 |
IL276383B1 (en) | 2023-09-01 |
IL276383A (en) | 2020-09-30 |
JP2023099094A (ja) | 2023-07-11 |
IL276383B2 (en) | 2024-01-01 |
TW202000700A (zh) | 2020-01-01 |
KR20200119274A (ko) | 2020-10-19 |
CA3088355A1 (fr) | 2019-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276383A (en) | Treatment of ophthalmological diseases | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
IL289405A (en) | Personalized treatment of eye diseases | |
IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
ZA201903003B (en) | Treatment of neurological diseases | |
SG11202010585WA (en) | New treatment of interstitial lung diseases | |
ZA202002075B (en) | Compounds, compositions and methods for treatment of eye disorders and skin diseases | |
IL269698B (en) | Methods for preventing or treating eye diseases | |
GB202015959D0 (en) | Treatment of diseases involving NAD | |
SG11202001595SA (en) | Angio-3 for treatment of retinal angiogenic diseases | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
SG11202007082PA (en) | Composition used for therapeutic treatment of skin disease | |
IL282361A (en) | Treatment for neurological diseases | |
IL282898A (en) | Ophthalmic compounds and methods for treating skin and eye diseases | |
GB201914516D0 (en) | Treatment of eye disease | |
SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
IL259381B (en) | Miravegron for the treatment of retinal diseases | |
GB201909438D0 (en) | Treatment of diseases | |
GB201604359D0 (en) | Treatment of tissue disorders | |
GB201805556D0 (en) | Treatment of ophthalmological conditions | |
GB201904764D0 (en) | Treatment of ophthalmological conditions | |
GB201811911D0 (en) | Treatment of disease | |
GB201811912D0 (en) | Treatment of disease | |
GB201810974D0 (en) | Treatment of disease |